FindTrial
Sign In

Safety & efficacy assessment of products on skin

To evaluate the in-vivo safety and efficacy of the skin care formulation in terms of non-comedogenic effect on healthy human subjects - Not Applicable

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020708
Enrollment
36
Registered
2019-08-14
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Oryza cream(TR001): Twice application on face for 28 days on whole face Control Intervention1: Not Applicable: Not Applicable

Sponsors

Alembic Pharmaceuticals Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Having oily or mixed oily skin on the face.

Exclusion criteria

Exclusion criteria: -For female: Do not take part in any family planning activities leading to pregnancy and breastfeeding -Do not take part in another study liable to interfere with this study -Do not take medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol). -Do not change her/his cosmetic habits apart from the particular conditions mentioned in the protocol, on the studied anatomic unit.

Design outcomes

Primary

MeasureTime frame
Safety & Efficacy assessment of productsTimepoint: Screening, T0 days, T14 days, T28 days—

Secondary

MeasureTime frame
SafetyTimepoint: Screening, T0 days, T14 days, T28 days—

Countries

India

Contacts

Public ContactMr Mohit Lalvani

Mascot Spincontrol India Pvt. Ltd.

siddheshwar@mascotspincontrol.in022-43349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026